Could a common nausea drug tame a dangerous heart rhythm?

NCT ID NCT05844501

Recruiting now Disease control Sponsor: Indiana University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether ondansetron, a drug usually used to prevent nausea from cancer treatment, can help people with atrial fibrillation (AFib). Researchers believe ondansetron may block a specific heart current that contributes to AFib. Eighty adults scheduled for AFib ablation will take either ondansetron or a placebo for 28 days to see if it reduces the time they spend in AFib and controls their heart rate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ondansetron
What this could lead to: If it works, this could point toward a new, safer treatment for atrial fibrillation using a common anti-nausea drug.
What could go wrong: This is a small, early-phase trial with only 80 participants. Ondansetron is not yet proven for heart conditions, and the effect may be modest or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION

Contacts and locations

Locations

Indiana Clinical Research Center
RECRUITING

Indianapolis, Indiana, 46202, United States
Indiana University Health Methodist Hospital
NOT_YET_RECRUITING

Indianapolis, Indiana, 46202, United States
Purdue University
RECRUITING

Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.